DG Capital Management (Massachusetts)’s BioMarin Pharmaceuticals BMRN Stock Holding History

DG Capital Management (Massachusetts)’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$1.02M	Buy	11,020 +1,340	+14%	+$126K	1%	45
2016 Q2	$753K	Sell	9,680 -630	-6%	-$53.6K	0.8%	54
2016 Q1	$850K	Buy	+10,310	New	+$839K	0.83%	50
2015 Q4	–	Sell	-26,130	Closed	-$2.75M	–	59
2015 Q3	$2.75M	Buy	26,130 +1,785	+7%	+$238K	1.85%	19
2015 Q2	$3.33M	Buy	+24,345	New	+$3.02M	2.01%	16

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

DG Capital Management (Massachusetts)'s BMRN Position: Q3 2016 in Review

DG Capital Management (Massachusetts) increased its BioMarin Pharmaceuticals (BMRN) stake by 14% in Q3 2016, buying an estimated $126K and bringing the position to 11,020 shares worth $1.02M. The position accounts for 1% of the portfolio, ranked #45.

DG Capital Management (Massachusetts) first reported a position in BMRN in Q2 2015 and has held it in 5 quarters since. The position peaked at $3.33M in Q2 2015. 422 funds tracked by Wall St. Rank hold BMRN as of Q3 2016.

DG Capital Management (Massachusetts) held 11,020 shares of BioMarin Pharmaceuticals worth $1.02M as of Q3 2016.
DG Capital Management (Massachusetts) bought 1,340 BioMarin Pharmaceuticals shares in Q3 2016, an estimated $126K.
BioMarin Pharmaceuticals made up 1% of DG Capital Management (Massachusetts)'s portfolio in Q3 2016, its #45 holding.
DG Capital Management (Massachusetts) first reported a position in BioMarin Pharmaceuticals in Q2 2015 and has held it in 5 quarters since.
DG Capital Management (Massachusetts)'s BioMarin Pharmaceuticals position peaked at $3.33M in Q2 2015.
422 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2016.

Based on DG Capital Management (Massachusetts)'s 13F filing for Q3 2016, filed 21 Oct 2016.